Results 1 to 10 of about 51,708 (157)

Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans [PDF]

Pharmacology Research & Perspectives
Aficamten, a cardiac myosin inhibitor, is being developed for the treatment of patients with symptomatic hypertrophic cardiomyopathy (HCM). The purpose of this study was to determine the absorption, metabolism, and excretion of aficamten.
Donghong Xu, Punag Divanji, Adrienne Griffith, Rajaa Sukhun, Kathleen Cheplo, Jianlin Li, Polina German   +6 more
doaj   +2 more sources

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges [PDF]

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj   +2 more sources

Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy [PDF]

Scientific Reports
Hypertrophic cardiomyopathy (HCM) remains the most common cardiomyopathy in humans and cats with few preclinical pharmacologic interventional studies. Small-molecule sarcomere inhibitors are promising novel therapeutics for the management of obstructive ...
Victor N. Rivas, Amanda E. Crofton, Carina E. Jauregui, Jalena R. Wouters, Betty S. Yang, Luke A. Wittenburg, Joanna L. Kaplan, Darren T. Hwee, Anne N. Murphy, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +12 more
doaj   +2 more sources

Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequences [PDF]

, 2009
Background: Intrauterine growth restriction is associated with an increased future risk for developing cardiovascular diseases. Hypoxia in utero is a common clinical cause of fetal growth restriction.
AM Katz, AN Tintu, Andrei Tintu, Anne Cathrine Staff, Arnold Schwartz, Asif Ahmed, BO Verburg, C Holubarsch, CP Leeson, DE Stewart, DJ Barker, E Villamor, EA Dumont, Edgar Hernandez-Andrade, Eduard Gratacos, Ellen Rouwet, Erdal Safak, EV Rouwet, Fatima Crispi, Ferdinand le Noble, FJ Giordano, G Pardi, H Haase, H Sugimoto, HQ Miao, I Shiojima, Ingo Morano, Irene Cetin, J Schaper, JL Morrison, Joep Brinkmann, JR Ingelfinger, KH Nicolaides, L Miquerol, L van Heerebeek, Leo Hofstra, M Feucht, M Ream, Marc Tjwa, Marc van Bilsen, Michael Jacobs, MR Zile, MR Zile, MW Gillman, N Ferrara, P Carmeliet, Peter Carmeliet, R Tatsumi, S Gupta, S Hein, S Hein, S Louey, SF Nagueh, Shakil Ahmad, SK Sharma, Stefan Verlohren, TA Fong, TM Nosek, Wouter H. Lamers, X Yue, Y Dor, Y Sugishita, Y Wu   +62 more
core   +28 more sources

Discovery of a novel cardiac-specific myosin modulator using artificial intelligence-based virtual screening

Nature Communications, 2023
Direct modulation of cardiac myosin function has emerged as a therapeutic target for both heart disease and heart failure. However, the development of myosin-based therapeutics has been hampered by the lack of targeted in vitro screening assays.
Priyanka Parijat, Seetharamaiah Attili, Zoe Hoare, Michael Shattock, Victor Kenyon, Thomas Kampourakis   +5 more
doaj   +1 more source

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +1 more source

Development and prevention of ischemic contracture (“stone heart”) in the pig heart

Frontiers in Cardiovascular Medicine, 2023
Stone heart (ischemic contracture) is a rare and serious condition observed in the heart after periods of warm ischemia. The underlying mechanisms are largely unknown and treatment options are lacking.
Mei Li, Mei Li, Zhi Qin, Erik Steen, Ann Terry, Bowen Wang, Björn Wohlfart, Stig Steen, Anders Arner   +8 more
doaj   +1 more source

Cycling Cross-Bridges Contribute to Thin Filament Activation in Human Slow-Twitch Fibers

Frontiers in Physiology, 2020
It has been shown that not only calcium but also strong binding myosin heads contribute to thin filament activation in isometrically contracting animal fast-twitch and cardiac muscle preparations. This behavior has not been studied in human muscle fibers
Alfredo Jesus López-Dávila, Joseph M. Chalovich, Stefan Zittrich, Birgit Piep, Faramarz Matinmehr, Andras Málnási-Csizmadia, Anna Á. Rauscher, Theresia Kraft, Bernhard Brenner, Robert Stehle   +9 more
doaj   +1 more source

Angiotensin II Facilitates Matrix Metalloproteinase-9-Mediated Myosin Light Chain Kinase Degradation in Pressure Overload-Induced Cardiac Hypertrophy

Cellular Physiology and Biochemistry, 2017
Background/Aims: Angiotensin II (Ang II) has been shown to promote cardiac remodeling during the process of hypertrophy. Myosin light chain kinase (MLCK), a specific kinase for the phosphorylation of myosin light chain 2 (MLC2), plays an important role ...
Shun Wang, Mian Cheng, Zhengqing Hu, Shan Hu, Qiang Zou, Xin Lai, Beilei Liu, Hong Jiang, Congxin Huang, Gang Wu   +9 more
doaj   +1 more source

An overview of the current genetic and phenotypical selection strategies to reduce the prevalence of feline hypertrophic cardiomyopathy = Een overzicht van de huidige genetische en fenotypische selectiestrategieën tegen hypertrofe cardiomyopathie bij de kat [PDF]

, 2020
Hypertrophic cardiomyopathy (HCM) is a common and potentially lethal heart disease in cats. To reduce its prevalence, breeding cats are frequently screened on the basis of their phenotype or genotype.
Broeckx, Bart, Peelman, Luc, Schipper, Tom, Smets, Pascale   +3 more
core   +1 more source